All In Biotech

Drug Trial Radar · NCT05342428

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

A Phase Ⅰb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of TLL-018 in Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Jun 10, 2022

Primary completion

Aug 30, 2023

Study completion Aug 30, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.

Conditions

  • Moderate to Severe Plaque Psoriasis

Interventions

  • TLL018 tabletsDrug

    Oral tablets administered at different doses BID daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEsTime frame: From day 1 to Weeks 12
  2. adverse events (AEs) according to severityTime frame: From day 1 to Weeks 12
  3. blood pressure from baselineTime frame: From day 1 to Weeks 12
  4. pulse rate from baselineTime frame: From day 1 to Weeks 12
  5. respiratory rate from baselineTime frame: From day 1 to Weeks 12
  6. temperature from baselineTime frame: From day 1 to Weeks 12
  7. clinical laboratory abnormalities compared to baselineTime frame: From day 1 to Weeks 12
  8. ECG parameters from baselineTime frame: From day 1 to Weeks 12
  9. physical examination findings from baselineTime frame: From day 1 to Weeks 12
  10. Cmax of TLL018Time frame: 0 hour (pre-dose - within 30 minutes prior to dosing), and at 0.5, 1, 2, 4 and 12 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 88 Jiefang Road, Shangcheng District, Hangzhou City, Zhejiang Province

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.